Predictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study

Diego Novick,1 Jihyung Hong,1 William Montgomery,2 Héctor Dueñas,3 Magdy Gado,4 Josep Maria Haro5 1Eli Lilly and Company, Windlesham, UK; 2Eli Lilly Australia Pty Ltd, West Ryde, Australia; 3Eli Lilly de Mexico, Mexico City, Mexico; 4Eli Lilly and Company, Riyadh, Saudi Arabi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Novick D, Hong J, Montgomery W, Dueñas H, Gado M, Haro JM
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://doaj.org/article/021e8ad80d89430daccb3c0894f13687
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:021e8ad80d89430daccb3c0894f13687
record_format dspace
spelling oai:doaj.org-article:021e8ad80d89430daccb3c0894f136872021-12-02T00:36:52ZPredictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study1178-2021https://doaj.org/article/021e8ad80d89430daccb3c0894f136872015-01-01T00:00:00Zhttp://www.dovepress.com/predictors-of-remission-in-the-treatment-of-major-depressive-disorder--peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021 Diego Novick,1 Jihyung Hong,1 William Montgomery,2 Héctor Dueñas,3 Magdy Gado,4 Josep Maria Haro5 1Eli Lilly and Company, Windlesham, UK; 2Eli Lilly Australia Pty Ltd, West Ryde, Australia; 3Eli Lilly de Mexico, Mexico City, Mexico; 4Eli Lilly and Company, Riyadh, Saudi Arabia; 5Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain Background: This study examined potential predictors of remission among patients treated for major depressive disorder (MDD) in a naturalistic clinical setting, mostly in the Middle East, East Asia, and Mexico. Methods: Data for this post hoc analysis were taken from a 6-month prospective, noninterventional, observational study that involved 1,549 MDD patients without sexual dysfunction at baseline in 12 countries worldwide. Depression severity was measured using the Clinical Global Impression of Severity and the 16-item Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR16). Depression-related pain was measured using the pain-related items of the Somatic Symptom Inventory. Remission was defined as a QIDS-SR16 score ≤5. Generalized estimating equation regression models were used to examine baseline factors associated with remission during follow-up. Results: Being from East Asia (odds ratio [OR] 0.48 versus Mexico; P<0.001), a higher level of depression severity at baseline (OR 0.77, P=0.003, for Clinical Global Impression of Severity; OR 0.92, P<0.001, for QIDS-SR16), more previous MDD episodes (OR 0.92, P=0.007), previous treatments/therapies for depression (OR 0.78, P=0.030), and having any significant psychiatric and medical comorbidity at baseline (OR 0.60, P<0.001) were negatively associated with remission, whereas being male (OR 1.29, P=0.026) and treatment with duloxetine (OR 2.38 versus selective serotonin reuptake inhibitors, P<0.001) were positively associated with remission. However, the association between Somatic Symptom Inventory pain scores and remission no longer appeared to be significant in this multiple regression (P=0.580), (P=0.008 in descriptive statistics), although it remained significant in a subgroup of patients treated with selective serotonin reuptake inhibitors (OR 0.97, P=0.023), but not in those treated with duloxetine (P=0.182). Conclusion: These findings are largely consistent with previous reports from the USA and Europe. They also highlight the potential mediating role of treatment with duloxetine on the negative relationship between depression-related pain and outcomes of depression. Keywords: antidepressant, duloxetine, selective serotonin reuptake inhibitors, Asia, Middle East, MexicoNovick DHong JMontgomery WDueñas HGado MHaro JMDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2015, Iss default, Pp 197-205 (2015)
institution DOAJ
collection DOAJ
language EN
topic Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Novick D
Hong J
Montgomery W
Dueñas H
Gado M
Haro JM
Predictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study
description Diego Novick,1 Jihyung Hong,1 William Montgomery,2 Héctor Dueñas,3 Magdy Gado,4 Josep Maria Haro5 1Eli Lilly and Company, Windlesham, UK; 2Eli Lilly Australia Pty Ltd, West Ryde, Australia; 3Eli Lilly de Mexico, Mexico City, Mexico; 4Eli Lilly and Company, Riyadh, Saudi Arabia; 5Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain Background: This study examined potential predictors of remission among patients treated for major depressive disorder (MDD) in a naturalistic clinical setting, mostly in the Middle East, East Asia, and Mexico. Methods: Data for this post hoc analysis were taken from a 6-month prospective, noninterventional, observational study that involved 1,549 MDD patients without sexual dysfunction at baseline in 12 countries worldwide. Depression severity was measured using the Clinical Global Impression of Severity and the 16-item Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR16). Depression-related pain was measured using the pain-related items of the Somatic Symptom Inventory. Remission was defined as a QIDS-SR16 score ≤5. Generalized estimating equation regression models were used to examine baseline factors associated with remission during follow-up. Results: Being from East Asia (odds ratio [OR] 0.48 versus Mexico; P<0.001), a higher level of depression severity at baseline (OR 0.77, P=0.003, for Clinical Global Impression of Severity; OR 0.92, P<0.001, for QIDS-SR16), more previous MDD episodes (OR 0.92, P=0.007), previous treatments/therapies for depression (OR 0.78, P=0.030), and having any significant psychiatric and medical comorbidity at baseline (OR 0.60, P<0.001) were negatively associated with remission, whereas being male (OR 1.29, P=0.026) and treatment with duloxetine (OR 2.38 versus selective serotonin reuptake inhibitors, P<0.001) were positively associated with remission. However, the association between Somatic Symptom Inventory pain scores and remission no longer appeared to be significant in this multiple regression (P=0.580), (P=0.008 in descriptive statistics), although it remained significant in a subgroup of patients treated with selective serotonin reuptake inhibitors (OR 0.97, P=0.023), but not in those treated with duloxetine (P=0.182). Conclusion: These findings are largely consistent with previous reports from the USA and Europe. They also highlight the potential mediating role of treatment with duloxetine on the negative relationship between depression-related pain and outcomes of depression. Keywords: antidepressant, duloxetine, selective serotonin reuptake inhibitors, Asia, Middle East, Mexico
format article
author Novick D
Hong J
Montgomery W
Dueñas H
Gado M
Haro JM
author_facet Novick D
Hong J
Montgomery W
Dueñas H
Gado M
Haro JM
author_sort Novick D
title Predictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study
title_short Predictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study
title_full Predictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study
title_fullStr Predictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study
title_full_unstemmed Predictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study
title_sort predictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study
publisher Dove Medical Press
publishDate 2015
url https://doaj.org/article/021e8ad80d89430daccb3c0894f13687
work_keys_str_mv AT novickd predictorsofremissioninthetreatmentofmajordepressivedisorderrealworldevidencefromanbsp6monthprospectiveobservationalstudy
AT hongj predictorsofremissioninthetreatmentofmajordepressivedisorderrealworldevidencefromanbsp6monthprospectiveobservationalstudy
AT montgomeryw predictorsofremissioninthetreatmentofmajordepressivedisorderrealworldevidencefromanbsp6monthprospectiveobservationalstudy
AT duenash predictorsofremissioninthetreatmentofmajordepressivedisorderrealworldevidencefromanbsp6monthprospectiveobservationalstudy
AT gadom predictorsofremissioninthetreatmentofmajordepressivedisorderrealworldevidencefromanbsp6monthprospectiveobservationalstudy
AT harojm predictorsofremissioninthetreatmentofmajordepressivedisorderrealworldevidencefromanbsp6monthprospectiveobservationalstudy
_version_ 1718403595055923200